GlobalData predicts that Lilly’s retatrutide could reach sales of $15.6bn in 2031. Image credit: Jennie Book / Shutterstock.com. Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight ...

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...

The two main players within this field are Novo Nordisk and Eli Lilly. Credit: zimmytws via Shutterstock. GLP-1 development has massively increased over the five years since 2020 and has become a ...

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study. Image credit: David Herraez Calzada via Shutterstock.com.

GlobalData’s analyst consensus forecast for gedatolisib is set to generate $827m in 2031. Credit: Jo Panuwat D/Shutterstock.com. At the European Society for Medical Oncology (ESMO) 2025 event, held in ...

Japanese pharmaceutical company Takeda has withdrawn itself from the cell therapy space amid its efforts to prioritise its portfolio. Image credit: Anusorn Nakdee via ShutterStock.com. Japanese pharma ...

Results indicated 10.6% of Winrevair subjects experienced a minimum of one clinical worsening event, compared to 36.9% in placebo. Credit: Sai Thaw Kyar / Shutterstock.com. MSD has announced positive ...